The Fight Against Myeloid Malignancies: Early Warning Signs and Emerging Innovations скачать в хорошем качестве

The Fight Against Myeloid Malignancies: Early Warning Signs and Emerging Innovations

In this episode of The HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center sits down with Uma Borate, MBBS, a leading hematologist at The Ohio State University, for an in-depth conversation on early detection in myeloid malignancies. With aggressive diseases like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) often progressing rapidly, early detection isn’t just beneficial—it’s critical. Drs. Banerjee and Borate begin by unpacking why timely identification can dramatically influence survival, treatment decisions, and long-term patient outcomes. The discussion explores the current diagnostic landscape, highlighting gaps such as the lack of standardized screening protocols and the limitations of existing tools. Dr. Borate shares real-world clinical insights into the challenges clinicians face, including silent precursor conditions, variable disease biology, and the difficulty of identifying malignancies before symptoms appear. From there, the conversation dives into practical strategies in use today, including routine blood tests, advanced genomic profiling, liquid biopsy technologies, and approaches to measurable residual disease (MRD) monitoring and relapse detection at a major academic center. In the final segment, the focus shifts to the future. The experts discuss how AI and machine learning could reshape early detection, improve risk stratification, and bring much-needed standardization to liquid biopsy approaches—paving the way for more predictive and personalized care in myeloid malignancies. 🎧 Listen in for a clinician-focused discussion on where early detection stands today—and where it’s headed next. Subscribe for more expert conversations on hematologic malignancies, emerging diagnostics, and the future of cancer care.